{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:44Z","timestamp":1793225984930,"version":"4.5.0"},"reference-count":20,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,12,11]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory or become resistant to steroids. Like many immune-related adverse events, little is known regarding the outcomes and optimal management of patients in whom steroids are ineffective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a single-center retrospective cohort study at a high-volume tertiary cancer center to evaluate the clinical course, management strategies and outcomes of patients treated for immune checkpoint pneumonitis with immune modulatory medications in addition to systemic steroids. Pharmacy records were queried for patients treated with both immune checkpoint blockade and receipt of additional immune modulators. Records were then manually reviewed to identify patients who received the additional immune modulators for immune checkpoint pneumonitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 2013 to 2020, we identified 26 patients treated for immune checkpoint pneumonitis with additional immune modulators in addition to steroids. Twelve patients (46%) were steroid-refractory and 14 (54%) were steroid-resistant. Pneumonitis severity included grade 2 (42%) or grade 3\u20134 (58%). Additional immune modulation consisted of tumor necrosis factor-alpha inhibitor (77%) and\/or mycophenolate (23%). Durable improvement in pneumonitis following initiation of additional immune modulators occurred in 10 patients (38%), including three patients (12%) in whom pneumonitis resolved and all immunosuppressants ceased. The rate of 90-day all-cause mortality\/hospice referral was 50%. At last follow-up, mortality attributable to pneumonitis was 23%. In addition to mortality from pneumonitis and cancer, 3 patients (12%) died due to infections possibly associated with immunosuppression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Steroid-refractory or -resistant immune checkpoint pneumonitis is uncommon but associated with significant morbidity and mortality. Additional immunomodulators can yield durable improvement, attained in over one third of patients. An improved understanding of the underlying biology of immune-related pneumonitis will be crucial to guide more precise and effective treatment strategies in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001884","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T11:33:02Z","timestamp":1612956782000},"page":"e001884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04438382","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-2425","authenticated-orcid":false,"given":"Jason","family":"Beattie","sequence":"first","affiliation":[{"name":"Pulmonary Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-827X","authenticated-orcid":false,"given":"Jia","family":"Luo","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Postow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Callahan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-5807","authenticated-orcid":false,"given":"Martin H","family":"Voss","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Genitourinary Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Genitourinary Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Chawla","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"2025100313022214000_9.2.e001884.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100313022214000_9.2.e001884.2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100313022214000_9.2.e001884.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177"},{"key":"2025100313022214000_9.2.e001884.4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108"},{"key":"2025100313022214000_9.2.e001884.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"2025100313022214000_9.2.e001884.6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100313022214000_9.2.e001884.7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s42399-020-00259-3","article-title":"Clinical outcomes of Anti-programmed death-1 Antibody\u2013Related pneumonitis in patients with non-small cell lung cancer","volume":"2","author":"Koyauchi","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"2025100313022214000_9.2.e001884.8","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint Inhibitor-related pneumonitis. An official American thoracic Society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025100313022214000_9.2.e001884.9","unstructured":"National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE) version 5.0, 2017. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"2025100313022214000_9.2.e001884.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025100313022214000_9.2.e001884.11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2025100313022214000_9.2.e001884.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100313022214000_9.2.e001884.13","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005"},{"key":"2025100313022214000_9.2.e001884.14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100313022214000_9.2.e001884.15","first-page":"100834","article-title":"Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature","volume":"27","author":"Petri","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"2025100313022214000_9.2.e001884.16","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-19"},{"key":"2025100313022214000_9.2.e001884.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322"},{"key":"2025100313022214000_9.2.e001884.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"2025100313022214000_9.2.e001884.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y"},{"key":"2025100313022214000_9.2.e001884.20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:02:30Z","timestamp":1759521750000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,10]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jitc-2020-001884"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001884","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}